profiting from the pandemic: will pharmaceutical giants use patents to limit access to covid drugs?
Published 4 years ago • 19K plays • Length 14:24Download video MP4
Download video MP3
Similar videos
-
2:37
the trump administration's sweetheart deal to a pharma company working on a covid-19 treatment
-
17:48
u.s. & other wealthy nations block effort to waive vaccine patent rights in blow to global south
-
6:45
waiving the vaccine patent may come down to giving pharmaceutical companies incentives
-
21:48
“a vaccine for the world”: u.s. scientists develop low-cost shot to inoculate global south
-
26:50
are pharmaceutical patents key to ending covid-19? | the agenda
-
10:07
as global pandemic worsens, u.s. keeps blocking vaccine patent waivers amid big pharma lobbying
-
1:14:41
prescription drug patents balancing innovation, access, and affordability
-
2:35:06
saving civilization: healthcare, tech, democracy (w/daniel schmachtenberger)
-
5:47
patents are preventing the manufacture of covid-19 vaccines - richard wolff [global capitalism]
-
4:54
how pharmaceutical companies game the patent system | tahir amin | big think
-
6:14
will scrapping vaccine patents help end the covid pandemic? | explain this
-
28:28
covid19 pandemic: intellectual property management for access to diagnostics, medicines and vaccines
-
10:45
how capitalism might screw up the vaccine. bleh.
-
24:16
who owns the rights to covid-19 vaccines? | inside story
-
16:46
covid: uk fighting patent-free covid vaccine proposals - bbc newsnight
-
7:33
nick dearden on how patent waivers will help boost global covid-19 vaccination efforts
-
1:47:55
access to vaccines and the limiting role of intellectual property rights and pharma monopolies
-
1:29:51
a fair shot vaccine patent protections and global access
-
2:35
covid-19 is no time for profiteering
-
2:13
drug manufacturers in poorer countries call for covid-19 vaccine patents to be lifted | abc news
-
5:36
why waiving vaccine patents isn’t enough to end the pandemic
-
1:02:04
patents and pandemics: innovation policy and the patent waiver petition at the wto